Candecor comp.

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candecor comp.

Property Description
Active ingredients Candesartan cilexetil, Hydrochlorothiazide
Form Tablet (Oral)
Pharmacological Class Angiotensin II Receptor Blocker (ARB) and Thiazide Diuretic combination
General Purpose Management of Hypertension (High Blood Pressure)
Origin Synthetic

The Fixed-Dose Combination Identity of Candecor comp.

Candecor comp. is a synthetic, prescription-only medicine that is formally classified as a fixed-dose combination product within the overarching category of antihypertensive agents. Administered via the oral route as a solid tablet, its structure simplifies treatment by incorporating two active ingredients into a single unit. This specific dual-ingredient form is widely employed when monotherapy has proven insufficient, a strategy clinically recognized for achieving greater therapeutic control. The objective of combining these two substances is to achieve an enhanced, sustained reduction in elevated arterial pressure through distinct, yet complementary, physiological pathways.


Composition and Dual Pharmacological Class

The medication’s composition consists of two active ingredients, each belonging to a different pharmacological class: Candesartan cilexetil and Hydrochlorothiazide. Candesartan cilexetil is a prodrug that is rapidly converted during absorption to the active compound, Candesartan, which belongs to the Angiotensin II Receptor Blocker (ARB) class. The second component, Hydrochlorothiazide, is a well-established Thiazide Diuretic. The combination of these two agents is intended for enhanced efficacy and blood pressure reduction compared to either ingredient used alone. This composition represents a rational approach supported by pharmacological evidence for achieving comprehensive pressure control.


General Therapeutic Purpose of Candecor comp.

The primary general purpose of the Candecor comp. combination is the effective and consistent blood pressure lowering for the long-term management of Hypertension. Candesartan's mechanism primarily addresses vascular tension by promoting blood vessel relaxation, while Hydrochlorothiazide’s action reduces fluid volume through increased salt and water excretion via the kidneys. This two-pronged intervention ensures that high blood pressure is addressed through two distinct physiological controls, resulting in a robust approach to arterial pressure maintenance that is generally considered a preferred second-line treatment option.

What side effects are possible with Candecor comp. ?

Possible Side Effects and Safety Information

The safety profile for Candecor comp., a fixed-dose combination of Candesartan cilexetil and Hydrochlorothiazide, is based on classifications detailed in official regulatory documents. Adverse reactions are grouped by frequency and the body system affected, ensuring a precise understanding of the potential risk spectrum.


Frequency Classification of Adverse Reactions

Adverse reactions are classified based on observed frequency in clinical studies and post-marketing surveillance. Common reactions (occurring in 1% to 10% of patients) typically include dizziness, headache, upper respiratory tract infection, and pharyngitis. Less frequently, reactions such as vomiting may occur. Rare reactions include severe hypersensitivity events like Angioedema, which involves swelling of the face or throat.


System-Organ Classes and Serious Safety Concerns

The documented adverse effects span multiple physiological systems, including Metabolism and Nutrition Disorders (e.g., changes in electrolyte levels, such as hypokalemia or hyperkalemia), Nervous System Disorders, and Renal and Urinary Disorders. The official label highlights serious safety concerns, including a Boxed Warning regarding fetal toxicity, advising against use during the second and third trimesters of pregnancy. Other serious documented reactions include the risk of Acute Renal Failure and a specific ophthalmic emergency, Acute Angle-Closure Glaucoma, linked to the hydrochlorothiazide component.


Population-Specific Safety Restrictions

The medicine is subject to defined constraints for specific patient groups and conditions. It is contraindicated in individuals with severe renal impairment (creatinine clearance less than 30 mL/min), anuria, and those with a known allergy to sulfa drugs. Use is also prohibited in patients with severe hepatic impairment or cholestasis due to the risk of precipitating hepatic coma. The risk of symptomatic hypotension is noted to be highest at the initiation of treatment, particularly in patients who are volume-depleted.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding overdose of Candecor comp. (Candesartan cilexetil/Hydrochlorothiazide) is derived strictly from official government regulatory documentation.

Documented Overdose Manifestations

An overdose is expected to result in an excessive drop in blood pressure, leading to several documented clinical signs. The primary manifestation is hypotension (severely low blood pressure), often accompanied by dizziness or syncope (fainting). Regulatory sources also list potential effects on heart rate, including both tachycardia (fast heart rate) and bradycardia (slow heart rate).

Severe Outcomes and Emergency Action

Excessive hypotension carries the risk of acute renal failure and, rarely, death, particularly in patients with pre-existing heart failure. Overdose may also result in significant electrolyte imbalance.

Immediate medical intervention is required. Regulatory instructions mandate that individuals seek emergency medical attention or call the Poison Help line immediately upon suspicion of an overdose.

Management and Monitoring

Property Official Overdose Information
Specific Antidote No specific antidote is available.
Management Strategy Symptomatic and supportive treatment is required, including close medical supervision.
Procedural Notes Volume repletion (fluid administration) may be necessary to correct symptomatic hypotension. Candesartan is not removed by hemodialysis.

All management must be performed under close medical supervision.

Therapeutic Uses of Candecor comp.

Candecor comp. is commonly used for the long-term management of Essential Hypertension in adults, relevant in clinical settings when sustained elevation in arterial pressure is not reaching target goals with single-agent therapy. This combination is applied when appropriate to help patients achieve and maintain target blood pressure goals, which supports general well-being during this chronic phase.

The therapeutic areas relevant to this combination include conditions where blood pressure is above target, situations where supportive management of systemic imbalance is appropriate, and contexts marked by increased discomfort or tension related to cardiovascular risk.

“The supportive management of high blood pressure may assist in maintaining long-term vascular stability.”

A primary benefit provided is the support for reducing the risk of major cardiovascular events. By working toward the management of blood pressure, Candecor comp. may assist with maintaining functional stability and supports the patient during episodes associated with increased systemic burden, helping to maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Supportive Management of Sustained Elevated Arterial Pressure Candecor comp. is applied when more comprehensive management of this chronic condition is required to stabilize readings, helping to maintain a sense of stability when blood pressure readings are more noticeable.

Regulatory References

  1. NIH DailyMed Label for Candesartan Cilexetil and Hydrochlorothiazide

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility profile for Candecor comp. (candesartan cilexetil/hydrochlorothiazide), strictly based on governmental regulatory labeling.

Populations That Must Not Use the Medicine (Contraindications)

Classification Exclusion Criteria
Physiological State Pregnancy (especially second and third trimesters) and Breastfeeding (Lactation).
Organ Dysfunction Severe renal impairment (creatinine clearance < 30 mL/min) or Anuria; Severe hepatic impairment and/or Cholestasis.
Hypersensitivity Documented allergy to candesartan cilexetil, hydrochlorothiazide, any excipient, or any other sulfonamide-derived drugs.
Comorbidity Gout; Concurrent use with aliskiren-containing drugs in patients with Diabetes Mellitus.
Age Children aged less than 1 year.

Populations with Restricted or Conditional Use

Adults (18 years and older) are the eligible age group for use, but the fixed combination is not indicated for initial therapy. Use requires caution and monitoring in patients with mild-to-moderate renal or hepatic impairment, aortic or mitral valve stenosis, or those who are volume/salt depleted (depletion must be corrected before starting therapy).

Use Not Established

Children and adolescents under 18 years of age have an unestablished safety and efficacy profile for this fixed-dose combination.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Candecor comp. (Candesartan cilexetil/Hydrochlorothiazide) based strictly on government regulatory labeling, such as the FDA and EMA.

Formal Contraindicated Combinations

The co-administration of Aliskiren is formally prohibited in patients with pre-existing Diabetes Mellitus or with moderate-to-severe renal impairment (Glomerular Filtration Rate < 60 mL/min/1.73 m^2).

Clinically Significant Interactions

Interacting Agent Official Regulatory Description
Lithium Preparations Reduced renal clearance of Lithium, leading to increased exposure and risk of toxicity.
NSAIDs (e.g., Aspirin > 3 g/day) May result in a reduced antihypertensive effect and increased risk of worsening renal function.
Potassium-Sparing Agents Increased risk of hyperkalemia (elevated serum potassium levels).
Other Antihypertensives May cause an additive hypotensive effect (increased blood pressure lowering).

Timing-Based Restrictions and Administration Notes

The absorption of the Hydrochlorothiazide component may be reduced by Resin Exchangers (e.g., Cholestyramine). To minimize this pharmacokinetic interference, Candecor comp. must be administered at least 4 hours before or 4–6 hours after the administration of the resin exchanger.

Co-administration with Alcohol, Barbiturates, or Narcotics is associated with an aggravated risk of orthostatic hypotension.

Mechanism of Action

Blocking Vascular Contraction via the RAAS

The Candesartan component acts within the domain of systemic vascular signaling by being a selective antagonist of the Angiotensin II Receptor Type 1 (AT1). This action prevents the hormone Angiotensin II from binding and causing blood vessel constriction, initiating a mechanistic cascade that leads to the relaxation and widening of arteries (vasodilation). This modulates the fundamental physiological function of Total Peripheral Resistance (TPR).


Modulating Renal Salt and Water Homeostasis

The Hydrochlorothiazide component engages the domain of renal tubular transport by acting as an inhibitor of the Sodium Chloride Cotransporter (NCC) in the distal convoluted tubule of the kidney. This molecular interference prevents the reabsorption of sodium and chloride, which osmotically increases the excretion of water, resulting in a reduction of the circulating fluid volume in the bloodstream.


Synergistic Dual Pathway Regulation

The two mechanisms are mechanistically complementary: the diuretic action on fluid volume intrinsically activates the Renin-Angiotensin-Aldosterone System (RAAS), a physiological feedback mechanism. The simultaneous AT1 receptor blockade by Candesartan prevents this compensatory RAAS activation from overriding the volume loss, contributing to the combined control of both vascular resistance and plasma volume.

Dosage and Administration Information

Official Administration Guidelines

Candecor comp. (candesartan cilexetil/hydrochlorothiazide) is an oral fixed-dose combination tablet, and its administration is strictly defined. The medicine is not intended for the initial treatment of hypertension; rather, it is used when a patient's blood pressure is not optimally controlled on monotherapy with candesartan or hydrochlorothiazide alone, or a lower combination dose.


Dosing and Administration Schedule

Instruction Detail
Route of Administration Oral use only.
Dosing Frequency The dose is taken once daily (q.d.).
Usual Dose One tablet once daily, corresponding to the effective, individually-titrated doses of the components. Available strengths are 16 mg/12.5 mg, 32 mg/12.5 mg, and 32 mg/25 mg. The maximal recommended dose is 32 mg/25 mg.
Intake Conditions The tablet may be administered with or without food.
Missed Dose If a patient misses a dose, they should not take a double dose to compensate. If more than 12 hours has passed, the missed dose should typically be skipped, and the next dose taken at the regular time.

Procedural Structure and Use-Context Constraints

Administration of the fixed combination should follow a step-wise process that establishes stability on the individual components before making the switch to the combination tablet at the corresponding dose. The maximal antihypertensive effect of any dose adjustment is generally achieved within four weeks of initiating that dose.

Specific restrictions apply to certain populations: the fixed combination is not recommended for patients with severe kidney impairment or moderate to severe liver impairment due to challenges in achieving the appropriate initial titration dose of the candesartan component. The tablet must be swallowed whole with water, and the use of the score line on some tablets is not intended for dividing the tablet into half doses.

Recent Clinical Evidence

Candecor comp.: Recent Clinical Evidence


Evidence for Use in Uncontrolled Essential Hypertension

The core research foundation for Candecor comp. was evaluated in multiple Randomized Controlled Trials (RCTs). These studies were studied for their use in adult patients diagnosed with essential hypertension whose high blood pressure was not reaching target goals with single-agent therapy.

Researchers examined what happened when patients were given the fixed-dose combination compared to those who received either Candesartan alone, Hydrochlorothiazide alone, or an inactive substance (placebo). The trials primarily examined the change in blood pressure metrics, specifically the sitting systolic and diastolic readings (SBP and DBP). These specific readings are considered surrogate endpoints, meaning they are measurements used in place of long-term health outcomes. Studies also explored the percentage of patients who reached pre-defined target blood pressure goals during the trial period.

Findings describe patterns observed in the studies where the combination was associated with changes in SBP and DBP reported by researchers to be more distinct than the changes seen when the components were used alone. This research provides context regarding the short-term patterns observed when blood pressure numbers were measured toward these targets. These studies primarily reflect observations made over short-term defined time intervals, typically lasting 8 to 12 weeks.


Long-Term Studies and Follow-Up

The majority of the primary trials researching the fixed-dose combination were conducted over short-term periods, usually concluding within three months. This means the research highlights changes measured during the study period but provides limited information regarding the long-term effects of the fixed-dose combination itself.

Some extensions of these studies, as well as separate observational research, have examined responses over more extended periods, sometimes up to one year. These longer observation periods contribute to the broader evidence landscape by helping to assess the patterns of blood pressure management observed over time. However, the available data are still emerging regarding the durability of these patterns over many years, as the main research focus was studied for the initial blood pressure measurements.


Research in Different Patient Groups

The clinical trials for Candecor comp. mainly focused on adult patients with a diagnosis of mild to moderate essential hypertension. The populations were observed in conditions where blood pressure remained high despite previous single-drug treatment.

Research also examined data for older adults (geriatric patients), but comprehensive data regarding the fixed-dose combination in patients with specific underlying organ diseases or those with the most severe systemic burden remains limited. The populations were observed in conditions where blood pressure remained high despite previous single-drug treatment. While the primary research population included a broad age range, specific, dedicated studies evaluating the use of the combination in children or adolescents are currently limited.


What the Research Does Not Fully Address

Research describes that the study patterns were consistent for blood pressure numbers, but the overall research base includes limitations concerning long-term clinical outcomes. Specifically, the data are still emerging for the direct link between the fixed-dose combination and the research exploring long-term vascular stability and functional support for the cardiovascular system. Research describes that the primary findings are derived from surrogate outcomes (blood pressure metrics), and long-term effects are not fully established directly from fixed-dose combination trials.

Key Studies & References NIH DailyMed Label for Candesartan Cilexetil and Hydrochlorothiazide Combination

Frequently Asked Questions (FAQ)

Common questions about Candecor comp. (FAQ)

Q: How quickly should I expect Candecor comp. to start working?

Official clinical data indicates that the components of Candecor comp. are absorbed and reach peak concentration in the bloodstream within a few hours. However, the maximal blood pressure-lowering effect is often observed within four weeks following a dosage change. This period is when the full effect is generally expected to become evident in clinical studies.

Q: Are there specific vitamins or supplements that should be avoided with Candecor comp.?

Official product information describes that taking Candecor comp. with potassium supplements or salt substitutes that contain potassium may increase the risk of hyperkalemia (elevated potassium levels). It is important for patients to inform their healthcare provider about all vitamins and supplements being taken.

Q: Is Candecor comp. safe for use by older patients?

Candecor comp. has been examined in older adults, and regulatory documents describe no routine dosage adjustments based on age alone. However, regulatory information highlights the importance of careful monitoring for changes in kidney function, as this is a general consideration for blood pressure management in geriatric patients.

Q: What are the requirements for monitoring (like blood tests) while on Candecor comp.?

Official guidelines describe that periodic monitoring of specific laboratory tests is necessary during treatment. These checks include reviewing serum electrolytes (like potassium and sodium) and renal function (kidney performance). This monitoring is performed to assess changes in the body's response, particularly regarding electrolyte levels and kidney function.

Q: Is it common for doctors to switch patients from other blood pressure drugs to Candecor comp.?

Official prescribing information indicates that Candecor comp. is formally used when a patient's high blood pressure is not optimally controlled with single-ingredient therapy. This describes the regulatory-defined context for considering a switch to the combination product. The fixed combination is not intended for the initial treatment of hypertension.

Q: What is the guidance on missing multiple doses of Candecor comp.?

The official instruction for missing a single dose is to skip it and take the next dose at the regular time. If a patient misses multiple sequential doses, official regulatory documents state that specific guidance should be sought from a healthcare professional.

Q: What percentage of patients experience severe side effects on Candecor comp.?

Serious adverse reactions, such as angioedema (swelling of the face or throat) or acute angle-closure glaucoma, are documented in regulatory sources. These events are classified as rare, meaning they occur very infrequently, as observed in clinical data.

Q: Does taking Candecor comp. at night versus morning make a difference?

Official administration instructions state that the medicine should be taken once daily. The prescribing information does not provide specific instruction that requires the dose to be taken at a particular time of day (morning versus night).

Q: Can Candecor comp. be used for heart failure?

The official therapeutic indication for the fixed-dose combination, Candecor comp., is solely for the management of hypertension (high blood pressure). Its use for heart failure is not specified in the regulatory label for this combination product.

Q: Do I need to take Candecor comp. forever?

Treatment for chronic hypertension is typically sustained to maintain blood pressure control. The final duration of use is determined through individual consultation with a healthcare professional.

Q: Is Candecor comp. the same as other candesartan medications?

No, Candecor comp. is a fixed-dose combination medicine containing Candesartan cilexetil plus a second active ingredient, Hydrochlorothiazide. This makes it chemically and pharmacologically different from medications that contain Candesartan monotherapy (just one ingredient).

Q: What is the difference between Candecor comp. and just Candecor?

Candecor comp. contains two active ingredients: Candesartan cilexetil and Hydrochlorothiazide. In contrast, 'just Candecor' typically refers to the monotherapy product, which contains only the Candesartan component. The addition of Hydrochlorothiazide is what makes it a combination product.

Q: Is Candecor comp. considered a 'water pill' because of one of its ingredients?

Yes, one of the active ingredients in the combination, Hydrochlorothiazide, belongs to the pharmacological class known as a Thiazide Diuretic. A diuretic is the medical term for the class of medicine often referred to by patients as a 'water pill.'

Q: What symptoms should trigger a call to the doctor after taking Candecor comp.?

Official information describes that rare but serious adverse reactions include Angioedema (swelling of the face, lips, tongue, or throat) and, specific to the diuretic component, rare cases of Acute Angle-Closure Glaucoma (acute vision changes or eye pain). These specific symptoms are documented as serious events.

Q: Is it normal to feel more tired when starting Candecor comp.?

Tiredness or fatigue is not classified as a common adverse effect in official documents. However, common side effects include dizziness and headache, which may occasionally contribute to a feeling of reduced energy as the body adjusts to the medicine.

Q: Can Candecor comp. affect my sleep?

Official adverse reaction data includes reports of insomnia (difficulty sleeping) occurring in some patients. This is not listed as a common occurrence in the prescribing information.

Q: Does grapefruit juice interact with Candecor comp.?

Official prescribing information for Candecor comp. does not describe a documented interaction between grapefruit juice and the medicine. The administration guidance indicates the tablet may be taken with or without food.

Q: Can Candecor comp. be taken by patients who have asthma?

There is no formal contraindication based solely on a diagnosis of asthma listed in the official documents. However, the hydrochlorothiazide component is a sulfonamide derivative, and caution is described for patients who have a known allergy to sulfa-derived drugs.

Q: Is there any research about Candecor comp. for uses other than blood pressure?

Clinical trials and research evidence reviewed in regulatory documents focus exclusively on the use of Candecor comp. for the treatment of essential hypertension (high blood pressure). Research evidence for uses outside of the approved indication is not contained in the official product information.

Q: Is Candecor comp. addictive or habit-forming?

Official labeling states that Candecor comp. is not associated with drug abuse or physical dependence potential. It is not considered an addictive or habit-forming medication.

Q: What should I know about stopping Candecor comp.?

Official guidance indicates that abruptly stopping the medicine may lead to an increase in blood pressure. Any decision regarding discontinuation should be made and managed under the supervision of a healthcare professional.

Q: Does Candecor comp. require any lifestyle changes, according to official guidance?

While the medicine works on its own, official guidance often includes the importance of incorporating dietary changes (such as reduced sodium intake) and physical activity as part of an overall high blood pressure management plan. These recommendations are part of the standard care for hypertension.

Q: Does Candecor comp. affect blood sugar levels?

The hydrochlorothiazide component is described in official warnings as potentially causing glucose intolerance. Official information highlights the need for caution, particularly in patients with existing diabetes.

Q: Does Candecor comp. interact with cold or flu medicines?

Official documents warn against the co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in many cold and flu remedies. Co-administration is documented to potentially reduce the blood pressure-lowering effect and increase the risk of worsening kidney function.

Q: Can Candecor comp. cause a persistent cough?

Official adverse reaction listings for the combination product do include reports of cough. This type of side effect is less frequently observed with this specific class of drug (Angiotensin II Receptor Blocker) than with related blood pressure medicines.

Q: What information about Candecor comp. is most important to share with a dentist or surgeon?

Regulatory caution advises informing surgical or dental staff about the use of Candecor comp. This is due to a documented risk of hypotension (low blood pressure) during procedures involving anesthesia.

Q: Can Candecor comp. affect libido or sexual function?

Adverse reaction listings for the medicine include reports of sexual dysfunction in some patients. This is not listed as a common occurrence in the prescribing information.

Q: What is the risk category for driving while taking Candecor comp., according to official advice?

Official advice states that patients should be aware of possible adverse effects, such as dizziness or fatigue, which may occasionally occur. If these effects are experienced, they could impair the ability to drive or operate machinery safely.

Q: Are the reported side effects for Candecor comp. permanent?

Adverse effects associated with the use of the medicine are generally described in regulatory documents as reversible upon cessation of treatment. Any decision regarding the use or stopping of the medicine should be managed and monitored by a healthcare provider.

Q: Is there a link between Candecor comp. and weight changes?

Official adverse reaction data includes reports of edema (fluid retention), which is the buildup of excess fluid that may affect body weight. Weight change itself is not listed as a common side effect in the prescribing information.

Q: Are there any documented interactions with herbal remedies and Candecor comp.?

The prescribing information provides specific warnings against the co-administration of potassium-containing supplements, which can include certain herbal and dietary products. This caution is due to the potential risk of hyperkalemia (elevated potassium levels).

How should Candecor comp. be stored and disposed of?

Official Storage and Disposal Instructions for Candecor comp.

Candecor comp. (Candesartan cilexetil/Hydrochlorothiazide tablets) must be stored under specific environmental controls as required by regulatory labeling to maintain product stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Must be protected from moisture and light; keep from freezing and temperatures exceeding 30 C.
Container Store in a tightly closed container and keep in the original packaging.
Safety Must be stored out of the reach and sight of children.

Disposal Requirements

Unused or expired tablets must not be disposed of via wastewater or routine household waste. Disposal should follow local regulatory requirements for unused medicinal products. Consult a healthcare professional or pharmacist on the appropriate method for discarding unneeded medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candecor comp.  found in:

A-Z Index: